Why Phase 3 Obesity Trials Take So Long — and Where Retatrutide Stands
Why Phase 3 Obesity Trials Take So Long — and Where Retatrutide Stands If you’ve ever wondered why obesity drugs take so long to reach patients — or why every story about retatrutide includes some version of ‘still in trials’ — there’s a real answer, and it’s not pharmaceutical-industry foot-dragging. Phase 3 obesity trials run […]
Retatrutide FDA Filing: Reading the Signals From Eli Lilly’s Pipeline
Retatrutide FDA Filing: Reading the Signals From Eli Lilly’s Pipeline If you’ve been trying to read the tea leaves on when retatrutide actually gets filed with the FDA — and what that filing will look like — you’re in good company. Pharmaceutical filing dates are rarely announced in advance. They have to be inferred from […]
TRIUMPH-2: What the Diabetes-Plus-Obesity Trial Adds to the Retatrutide Picture
TRIUMPH-2: What the Diabetes-Plus-Obesity Trial Adds to the Retatrutide Picture If you have type 2 diabetes and obesity, and you’ve been following the retatrutide pipeline for the trial that actually applies to you, the answer is TRIUMPH-2. It’s the larger and longer of the two Phase 3 retatrutide trials in adults with type 2 diabetes […]
TRIUMPH-5: The Trial That Will Actually Compare Retatrutide and Tirzepatide Head-to-Head
TRIUMPH-5: The Trial That Will Actually Compare Retatrutide and Tirzepatide Head-to-Head If you’ve been trying to figure out how retatrutide actually compares with tirzepatide — not via cross-trial guesswork, but in a real head-to-head trial — there’s exactly one Phase 3 trial designed to answer that question. It’s called TRIUMPH-5, and despite what the trial-numbering […]
TRIUMPH-4 and the Knee Osteoarthritis Surprise: What the First Phase 3 Retatrutide Trial Actually Showed
TRIUMPH-4 and the Knee Osteoarthritis Surprise: What the First Phase 3 Retatrutide Trial Actually Showed If you’ve struggled with knee pain alongside excess weight, the December 2025 TRIUMPH-4 results are the kind of data that turn heads. Participants on the highest dose of retatrutide lost an average of 28.7% of their body weight at 68 […]
What TRANSCEND-T2D-1 Tells Us About Retatrutide in Type 2 Diabetes
What TRANSCEND-T2D-1 Tells Us About Retatrutide in Type 2 Diabetes If you have type 2 diabetes and you’ve been watching the retatrutide story unfold, March 2026 was a milestone you probably noticed. Eli Lilly reported topline results from TRANSCEND-T2D-1 — the first Phase 3 retatrutide trial in adults with type 2 diabetes to read out. […]
TRIUMPH-1 Explained: What to Expect From Retatrutide’s Pivotal Phase 3 Obesity Readout
TRIUMPH-1 Explained: What to Expect From Retatrutide’s Pivotal Phase 3 Obesity Readout If you’ve been following retatrutide for months — refreshing news pages, tracking Eli Lilly’s pipeline updates, and waiting for the obesity numbers everyone keeps talking about — you’re not alone. The trial that will actually decide retatrutide’s case for FDA approval as a […]
Eli Lilly’s Q1 2026 Update on Retatrutide: What the Latest Earnings Call Tells Us About Approval Timing
Eli Lilly’s Q1 2026 Update on Retatrutide: What the Latest Earnings Call Tells Us About Approval Timing If you’ve been refreshing news pages every quarter trying to figure out when retatrutide is actually going to be available, the most useful single source isn’t a press release — it’s the earnings call transcript. That’s where Eli […]
What Is a Triple Agonist?
Learn what a triple agonist is, how it works, and why researchers are studying compounds like retatrutide. Clear, science-based explanation for beginners.
The Future of GLP-1, GIP, and Glucagon Drugs
Explore the future of obesity treatments with GLP-1, GIP, and glucagon drugs. Learn how investigational therapies like retatrutide fit into next-generation research.